Perrigo Co. Plc (PRGO)
14.48
+0.04
(+0.31%)
USD |
NYSE |
Sep 02, 16:00
14.48
0.00 (0.00%)
After-Hours: 16:04
Perrigo Research and Development Expense (TTM) : 95.00M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 95.00M |
| March 31, 2026 | 93.30M |
| December 31, 2025 | 95.40M |
| September 30, 2025 | 101.50M |
| June 30, 2025 | 102.60M |
| March 31, 2025 | 110.00M |
| December 31, 2024 | 112.30M |
| September 30, 2024 | 114.10M |
| June 30, 2024 | 117.70M |
| March 31, 2024 | 120.50M |
| December 31, 2023 | 122.60M |
| September 30, 2023 | 125.50M |
| June 30, 2023 | 125.70M |
| March 31, 2023 | 125.00M |
| December 31, 2022 | 123.20M |
| September 30, 2022 | 120.90M |
| June 30, 2022 | 118.70M |
| March 31, 2022 | 120.20M |
| December 31, 2021 | 122.00M |
| September 30, 2021 | 124.70M |
| June 30, 2021 | 139.70M |
| March 31, 2021 | 137.10M |
| December 31, 2020 | 133.90M |
| September 30, 2020 | 160.30M |
| June 30, 2020 | 161.70M |
| Date | Value |
|---|---|
| March 31, 2020 | 175.20M |
| December 31, 2019 | 187.50M |
| September 30, 2019 | 172.70M |
| June 30, 2019 | 172.40M |
| March 31, 2019 | 220.40M |
| December 31, 2018 | 218.60M |
| September 30, 2018 | 220.90M |
| June 30, 2018 | 215.60M |
| March 31, 2018 | 166.30M |
| December 31, 2017 | 167.70M |
| September 30, 2017 | 162.30M |
| June 30, 2017 | 174.10M |
| March 31, 2017 | 178.50M |
| December 31, 2016 | 184.00M |
| September 30, 2016 | 189.10M |
| June 30, 2016 | 180.50M |
| March 31, 2016 | 196.10M |
| December 31, 2015 | 186.20M |
| September 30, 2015 | 177.60M |
| June 30, 2015 | 180.70M |
| March 31, 2015 | 155.60M |
| June 30, 2014 | 152.50M |
| March 31, 2014 | 145.46M |
| December 31, 2013 | 129.28M |
| September 30, 2013 | 120.10M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Avadel Pharmaceuticals Plc | 39.89M |
| Jazz Pharmaceuticals Plc | 815.61M |
| GH Research Plc | 46.71M |
| Cosmo NV | 36.52M |
| Viatris, Inc. | 995.00M |